Stevens-Johnson syndrome is an acquired condition resulting from an immune-mediated hypersensitivity response. It is not caused by an inherited germline genetic change, and Mendelian inheritance patterns are not applicable. Specific triggering agents and mechanistic details beyond the skin and mucosal epithelial destruction described in the definition are not further detailed in this packet.

Diagnostic information specific to Stevens-Johnson syndrome is not detailed in this packet. Clinical recognition relies on the characteristic pattern of skin and mucosal involvement, with assessment of the percentage of affected body surface area serving as a key criterion for distinguishing SJS from the related condition TEN.

Specific treatment details for Stevens-Johnson syndrome are not captured in this packet. Management of this condition is guided by the severity and extent of mucocutaneous involvement and involves multidisciplinary clinical evaluation. No treatments specifically captured as approved are present in this packet.

Outcome data for Stevens-Johnson syndrome are not detailed in this packet. Individual prognosis depends on the severity of the reaction, the extent of mucosal involvement, and the clinical course.

Several clinical trials are currently investigating new therapeutic approaches for Stevens-Johnson syndrome and the related condition toxic epidermal necrolysis. Active investigations include studies of immunomodulatory approaches targeting immune pathways implicated in the condition, biologic agents, mesenchymal stromal cell therapy, and autologous serum preparations for ocular complications. Observational registry studies are also under way to improve understanding of outcomes across affected individuals. Individuals interested in current trial opportunities can search the ClinicalTrials.gov database.